Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 14/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 14/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 14/20 | 0.55 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | F3 | P13726 | 1/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 13/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 13/20 | 0.51 |
| ▸ | PRKAG3 | Q9UGI9 | 13/20 | 0.51 |
| ▸ | PRKAG2 | Q9UGJ0 | 13/20 | 0.51 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20839333 | 0.89 | F7 (0.47) | PRKAG1PRKAA1PRKAB1HAO1F7 | |
| SCHEMBL27814101 | 0.88 | ROCK1 (0.49) | PRKAG1PRKAA1PRKAB1F7F3 | |
| SCHEMBL7379535 | 0.86 | MAP2K4 (0.61) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL30443279 | 0.86 | MAP2K4 (0.61) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL17324736 | 0.85 | ROCK1 (0.47) | PRKAG1PRKAA1PRKAB1F7F3 | |
| SCHEMBL16246796 | 0.85 | JAK2 (0.48) | F7F3MAP2K4ROCK1 | |
| SCHEMBL19997303 | 0.81 | PAK1 (0.64) | PRKAG1PRKAA1PRKAB1ROCK1 | |
| SCHEMBL4793264 | 0.81 | KDM4E (0.63) | PRKAG1PRKAA1PRKAB1MAP2K4ROCK1 | |
| SCHEMBL22518544 | 0.81 | ROCK1 (0.53) | ROCK1 | |
| SCHEMBL17321393 | 0.81 | DYRK1A (0.48) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106103427-B | Indazole compound and preparation method thereof | 科学与工业研究会 | 2019-07-16 | — | — | CN | claimed |
| EP-3027605-B1 | NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2017-11-08 | — | — | EP | claimed |
| US-9737510-B2 | Indazole compounds and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-08-22 | — | — | US | claimed |
| CN-106103427-A | New indazole compound and preparation method thereof | 科学与工业研究会 | 2016-11-09 | — | — | CN | claimed |
| US-20160185759-A1 | NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-30 | — | — | US | claimed |
| EP-3027605-A1 | NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2016-06-08 | — | — | EP | claimed |
| WO-2015015519-A1 | NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-02-05 | — | — | WO | claimed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | claimed |
| JP-2006500348-A | — | — | 2006-01-05 | — | — | JP | claimed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | claimed |
| WO-2005014554-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-17 | — | — | WO | claimed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| US-12637447-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective mcl-1 inhibitors and as dual mcl-1/bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260022131-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-22 | — | — | US | disclosed |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| US-6316617-B1 | FOR TREATING PHYSIOLOGICAL DISORDERS ASSOCIATED WITH AN EXCESS OF NEUROPEPTIDE Y, SUCH AS FEEDING DISORDERS AND CERTAIN CARDIOVASCULAR DISEASES, MEDICAL DIAGNOSIS | NEUROGEN CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6133265-A | Certain amido- and amino- substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands | NEUROGEN CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0918761-A1 | CERTAIN AMIDO- AND AMINO-SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTITE Y1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998003494-A1 | CERTAIN AMIDO- AND AMINO-SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTITE Y1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185759-A1 | NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF | GPR119, INSR, CYP11B1 | PRKAG1 1356/4885PRKAA1 1150/4885PRKAB1 1364/4885 |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, DRD3 | PRKAG1 4137/4885PRKAA1 3186/4885PRKAB1 3838/4885 |
| US-12637447-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective mcl-1 inhibitors and as dual mcl-1/bcl-2 inhibitors | MCL1, BCL2L1, BCL2L2 | PRKAG1 2527/4885PRKAA1 1474/4885PRKAB1 2336/4885 |
| US-20260022131-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | CLN6, NR2E3, CBR3 | PRKAG1 2139/4885PRKAA1 1337/4885PRKAB1 1838/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | PRKAG1 3516/4885PRKAA1 2765/4885PRKAB1 3327/4885 |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | PRKAG1 3651/4885PRKAA1 2093/4885PRKAB1 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.